Core Viewpoint - The article discusses the forced delisting of *ST Suwu (Jiangsu Wuzhong) from the A-share market due to serious financial fraud, highlighting the company's significant stock price decline and the implications for the medical beauty industry [1][3]. Summary by Sections Company Delisting - *ST Suwu has been mandated to delist from the Shanghai Stock Exchange, with the last trading date expected to be December 29, 2025, following a decision by the exchange due to major legal violations [3]. - The company’s stock price plummeted from over 9 yuan at the beginning of the year to below 1 yuan, marking a decline of over 90% [1][3]. Financial Misconduct - The China Securities Regulatory Commission (CSRC) identified that *ST Suwu's annual reports from 2020 to 2023 contained false information, leading to the delisting decision [3]. - The company was found to have inflated revenue and profits through non-commercial transactions with related parties, resulting in significant discrepancies in reported financials [7]. - Specific figures include inflated revenues of 4.95 billion yuan, 4.69 billion yuan, 4.31 billion yuan, and 3.77 billion yuan for the years 2020 to 2023, respectively, along with inflated profits totaling 145.83 million yuan over the same period [7]. Corporate Governance Issues - The company concealed changes in its actual controlling shareholder, which was a significant violation impacting market transparency [6]. - The actual controller changed in February 2018, but the company continued to report the previous controller in its annual reports until 2023 [6]. Regulatory Actions - The CSRC imposed a fine of 10 million yuan on *ST Suwu and additional penalties on its actual controllers, including a 10-year ban from the securities market for the main controller [8]. - The exchange publicly reprimanded the company and its responsible individuals, emphasizing the importance of compliance and truthful financial reporting in the capital market [5][8]. Business Challenges - Prior to the delisting, *ST Suwu faced multiple operational challenges, including a significant drop in stock price and ongoing disputes regarding exclusive sales rights for a key product, AestheFill [10][11]. - The company reported a 63.93% decline in revenue in the third quarter of 2025, reflecting the adverse impact of these challenges on its financial performance [12]. Industry Implications - The case of *ST Suwu serves as a warning to the medical beauty industry regarding the risks associated with financial misconduct and the importance of maintaining transparent corporate governance [5][12].

Core Viewpoint - ST Lifan (300344.SZ) resumed trading with a limit down at 2.69 yuan, with over 1.4 million shares on hold, resulting in a market capitalization of 1.726 billion yuan; the total trading volume exceeded 3.8 million yuan for the day [1] Group 1: Company Financial Irregularities - On November 28, ST Lifan announced it received an "Administrative Penalty and Market Ban Notice" due to potential false records in its annual reports from 2021 to 2023, which may lead to mandatory delisting [1] - From 2021 to 2023, ST Lifan inflated its revenue by a total of 638 million yuan and costs by 628 million yuan through various means including agency business, financing trade, and false trade [1] - The inflated figures for each year are as follows: - 2021: Revenue inflated by 280 million yuan, costs inflated by 277 million yuan - 2022: Revenue inflated by 312 million yuan, costs inflated by 305 million yuan - 2023: Revenue inflated by 46 million yuan, costs inflated by 45 million yuan [1] Group 2: Market Reaction - Following the announcement, ST Lifan's stock was placed under delisting risk warning, changing its name from "ST Lifan" to "*ST Lifan (Rights Protection)" effective December 2 [1]

Core Viewpoint - Jiangsu Wuzhong's stock will be delisted due to serious violations including financial fraud and failure to disclose the actual controlling shareholder [1][3] Group 1: Regulatory Actions - The China Securities Regulatory Commission (CSRC) has issued an administrative penalty decision against Jiangsu Wuzhong, citing continuous financial fraud over four years from 2020 to 2023 [2][3] - Jiangsu Wuzhong has been found to have inflated its operating income by a total of 1.771 billion yuan and its total profit by 75.9975 million yuan during this period [3] - The company is also accused of providing non-operating funds to related parties, with a balance of 1.693 billion yuan by the end of 2023, accounting for 96.09% of the disclosed net assets [3][4] Group 2: Management Accountability - Key individuals, including Qian Qunshan, who held multiple executive roles, have been penalized for their involvement in the financial misconduct [3][4] - The CSRC has determined that Qian Qunshan is primarily responsible for the financial fraud, including concealing the actual controlling shareholder's identity and orchestrating non-commercial trade activities [3][4] Group 3: Delisting Process - Jiangsu Wuzhong's stock will enter a delisting preparation period starting December 9, with a trading duration of 15 days, and the expected last trading day is December 29 [5] - The stock will be traded on the risk warning board during this period, with the first trading day having no price limit, followed by a daily limit of 10% [5] - Prior to the announcement of the suspension, Jiangsu Wuzhong's stock experienced a five-day consecutive limit-up, with a total increase of 27.84%, despite warnings of potential delisting [5]

连续多年财务造假被查处，沈阳远大智能（002689）工业集团股份有限公司（以下简称"远大智能"）及 相关责任人日前收到辽宁证监局出具的《行政处罚事先告知书》。根据交易所上市规则相关规定，远大 智能股票自12月2日起将被实施其他风险警示，证券简称将由"远大智能"变更为"ST远智"。 非法确认租赁业务收入方面，远大智能在未取得交房验收确认单的情况下仍确认对应租赁收入，导致 2021年虚增营业收入914.85万元，占当期报告记载营业收入的0.94%；虚增利润总额848.17万元，占当 期报告记载利润总额绝对值的62.47%。 前述两项违法行为，致使远大智能2019年、2020年、2021年三个年度的年度报告和2022年半年度报告存 在虚假记载。 "定期报告是上市公司对经营成果、财务状况及治理情况的全面总结，不仅能为投资者提供关键信息， 帮助其评估公司价值和风险，同时也可以引导社会资源流向更具效益的企业，促进资本市场的高效运 作。"深圳优品投资顾问有限公司投资顾问李鹏岩在接受《证券日报》记者采访时表示，上市公司财务 报表失真不仅可能误导投资者决策，同时也会侵蚀市场信任，扰乱市场秩序，破坏价格发现机制。 合计拟处罚21 ...

2025.11.30 本文字数：2666，阅读时长大约4分钟 作者 |第一财经 周楠 连续三年虚增营收，其中两年的虚增金额占到当期总营收五成以上，控股股东正在推进破产重整的ST 立方（300344.SZ），因上述财务造假问题吃下大额罚单，并由此拉响退市"警钟"。 ST立方最新披露，公司被查明存在年报虚假记载，2021年至2023年累计虚增营收超6亿元，安徽证监局 对公司及10名相关责任人合计罚款4000万元，多人被采取10年市场禁入措施。 记者关注到，在此番被查明财务造假之前，ST立方去年至今两度更正会计差错，2024年年报被出具"非 标"意见，今年4月底被实施ST。 如今，ST立方在"戴帽"半年之后还将"披星"。根据安排，该股将于12月1日开市起停牌，次日复牌后股 票简称变更为*ST立方。公司同时提到，若后续正式处罚出炉，公司被认定触及重大违法强制退市情 形，将被终止上市。 基本面上，ST立方已亏损累累，近五年扣非净利润累计亏损超10亿元。公司控股股东正在推进破产重 整，持股5%以上股东的部分持股近期则遭遇流拍。 连续三年财务造假 今年年报季里，ST立方遭遇年报"非标"，并因此被实施其他风险警示。4月30日 ...

Group 1 - ST Lifan has received a notice of administrative punishment and market ban due to long-term systematic financial fraud, leading to potential forced delisting from the capital market [1][2] - The company reported false financial statements for the years 2021, 2022, and 2023, which may trigger significant violations leading to mandatory delisting [1][2] - The total amount of false revenue reported for 2021 and 2022 reached 592 million, accounting for 50.91% of the total disclosed annual revenue for those years, directly triggering delisting standards [2] Group 2 - The company’s stock will be suspended from trading starting December 1, 2025, and will resume trading on December 2, 2025, with a risk warning label changing from "ST Lifan" to "*ST Lifan" [1] - Legal actions for compensation have begun against ST Lifan, with evidence supporting future investor lawsuits [1][2] - The auditing firm involved in ST Lifan's financial fraud, Zhongxing Huaguang, is under investigation by the China Securities Regulatory Commission [2]

Core Viewpoint - ST Lifan has been found guilty of financial fraud over three consecutive years, leading to significant penalties and potential delisting from the stock market [1][2][5]. Group 1: Financial Fraud Details - From 2021 to 2023, ST Lifan inflated its revenue by a total of 638 million yuan and costs by 628 million yuan through various fraudulent activities [1]. - The specific annual breakdown shows that in 2021, revenue was inflated by 280 million yuan and costs by 277 million yuan; in 2022, revenue was inflated by 312 million yuan and costs by 305 million yuan; and in 2023, revenue was inflated by 46 million yuan and costs by 45 million yuan [2][4]. - The inflated revenue for 2021 and 2022 combined reached 592 million yuan, accounting for 50.91% of the total reported revenue for those years, triggering mandatory delisting regulations [2]. Group 2: Penalties and Consequences - The China Securities Regulatory Commission (CSRC) plans to impose a fine of 10 million yuan on ST Lifan and a total of 30 million yuan on ten responsible individuals, including a 10-year market ban for three key individuals [1][6]. - The Shenzhen Stock Exchange will initiate delisting procedures, with ST Lifan's stock being suspended for one day starting December 1 and then resuming trading under a risk warning as "*ST Lifan" on December 2 [1][6]. - The accounting firm Zhongxing Caiguanghua has faced scrutiny for issuing unqualified audit reports for ST Lifan from 2021 to 2023, and the CSRC has opened an investigation into the firm's conduct [6][7].

Group 1 - The central bank held a meeting to coordinate efforts against virtual currency trading speculation [1] - The central bank and the Ministry of Science and Technology jointly convened the first meeting of the Financial Technology Coordination Mechanism [1] - The China Securities Regulatory Commission (CSRC) is targeting financial fraud, holding both issuers and intermediary institutions accountable [1] Group 2 - The Ministry of Industry and Information Technology (MIIT) is addressing the "involution" competition in the power and energy storage battery industry through legal and regulatory measures [1] - In November, China's manufacturing PMI rose to 49.2, indicating a slight improvement in manufacturing activity [1] - The National Space Administration established a Commercial Space Office to promote high-quality development in the commercial space sector [1] Group 3 - New regulations for live-streaming e-commerce are expected to be introduced [1] - Withdrawals exceeding 50,000 will no longer require registration [1] - Major oil-producing countries announced plans to maintain a production freeze for the first three months of next year [1]

来源：运营商财经网 财报数据显示，瑞幸咖啡三季度实现营业收入152.9亿元，同比增长50.2%，GMV为173.20亿元，归母净 利润为12.8亿元，同比下降1.9%，呈现增收不增利的情形。 此外，瑞幸咖啡三季度配送费用涨至28.9亿元，同比大幅增长211.4%，费用占比从9.1%上升到18.9%， 安静对此表示，虽然配送费大幅增长，但"单笔订单的配送费用同比有所下降"，这反映出规模化运营效 率的提升。 瑞幸咖啡官网显示，安静于1998年获得中国人民大学经济学学士学位，后于2010年取得斯坦福商学院管 理学硕士学位。本科毕业后，安静任职于普华永道北京公司，担任高级会计师职务。2003年，安静任职 于亿友娱乐公司，2007年又到酷洛夫科技有限公司任职，2010年跳槽至热酷媒体有限公司，任高级企业 财务和管理职务。 2013年安静进入蓝汛通信技术有限责任公司，担任其首席财务官一职，2016年再次跳槽至58到家，任首 席财务官。2022年，加入瑞幸咖啡，担任公司的首席财务官。 可以看出，安静的履历十分丰富，积累了丰富的财务管理经验。对于曾经因财务造假被摘牌退市，而又 打算重新上市的瑞幸咖啡来说，公司首席财务官的人选 ...

ST立方最新披露，公司被查明存在年报虚假记载，2021年至2023年累计虚增营收超6亿元，安徽证 监局对公司及10名相关责任人合计罚款4000万元，多人被采取10年市场禁入措施。 记者关注到，在此番被查明财务造假之前，ST立方去年至今两度更正会计差错，2024年年报被出 具"非标"意见，今年4月底被实施ST。 2025.11. 30 本文字数：2666，阅读时长大约4分钟 作者 | 第一财经 周楠 连续三年虚增营收，其中两年的虚增金额占到当期总营收五成以上，控股股东正在推进破产重整的 ST立方（300344.SZ），因上述财务造假问题吃下大额罚单，并由此拉响退市"警钟"。 如今，ST立方在"戴帽"半年之后还将"披星"。根据安排，该股将于12月1日开市起停牌，次日复牌后 股票简称变更为*ST立方。公司同时提到， 若后续正式处罚出炉，公司被认定触及重大违法强制退 市情形，将被终止上市。 基本面上，ST立方已亏损累累，近五年扣非净利润累计亏损超10亿元。公司控股股东正在推进破产 重整，持股5%以上股东的部分持股近期则遭遇流拍。 连续三年财务造假 早前，ST立方4月底披露，公司因定期报告涉嫌信披违法违规被证监会立案。 ...